-- Robert Preidt
WEDNESDAY, Dec. 15 (HealthDay News) -- Genes that predict length
of survival and help guide treatment for patients with non-small
cell lung cancer have been identified by U.S. researchers.
The investigators took samples of lung tumors and nearby healthy
lung tissue from 30 patients and examined the samples for the
presence of messenger ribonucleic acid (mRNA) associated with 48
known genes for molecules called nuclear hormone receptors.
They then compared the active genes with patient outcomes and
found that the expression of genes for certain nuclear hormone
receptors helped predict patient survival.
According to the results, patients with two specific nuclear
hormone receptors in their tumor tissue lived the longest. The two
"biomarkers" were the short heterodimer partner and the
"Patient responses to cancer treatment vary widely and often depend on subtle biological differences among tumors," study co-lead author Dr. David Mangelsdorf, chairman of pharmacology at the University of Texas Southwestern Medical Center, said in a facility news release.
"These findings are important because the ability to determine which genes are being expressed in each person's tumor, as well as a patient's likely survival time, can guide physicians to the most effective and appropriate personalized treatments," he added.
The study was published in the Dec. 14 edition of the journal
The American Cancer Society has more about
non-small cell lung cancer.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.